Famitinib malate capsules | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- Both uses require combination with camrelizumab for recurrent or metastatic cervical cancer: (1) after failure of platinum-based chemotherapy, without previous bevacizumab treatment; or (2) as first-line treatment of PD-L1-positive disease (CPS >=1), confirmed by a fully validated test.
- Indication source and scope
- 2026-07-21
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label. Original manufacturer page images have been preserved in order.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Restricted to use with camrelizumab for recurrent or metastatic cervical cancer after failure of platinum-based chemotherapy, without previous bevacizumab treatment.
- Insurance period
- 2026-01-01 to 2027-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.cde.org.cn/main/news/viewInfoCommon/b93aba16ec47467317057dca4aac8437
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.hengrui.com/product/innovativeMedicine.html?type=1
Open the interactive record, public price references and discussions